Sale

Autologous Cell Therapy Market

Global Autologous Cell Therapy Market Size, Trends, Report: By Therapy: Autologous Stem Cell Therapy, Autologous Cellular Immunotherapies; By Source: Bone Marrow, Epidermis, Others; By Application: Oncology, Musculoskeletal Disorder, Blood Disorder, Others; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Global Autologous Cell Therapy Market Outlook

The autologous cell therapy market size was valued at USD 7.8 billion in 2023, driven by the emphasis on precision medicine to treat chronic diseases across the globe. The market is expected to grow at a CAGR of 19.4% during the forecast period of 2024-2032, with the values likely to rise from USD 9.3 billion in 2024 to USD 38.4 billion by 2032.

 

Autologous Cell Therapy: Introduction

Autologous cell therapy is a technique that uses an individual’s own cells or tissues to be processed and expanded outside the body and later reintroduced into the donor. This therapy provides advantages like biocompatibility, lower risk from systemic immunological reactions and disease transmission related to external grafts or cells.

 

Autologous cell therapy finds its application in dermatology, oncology, musculoskeletal as well as autoimmune disorders. It is used in treating burns and pressure ulcers, helping wound healing, expediate postoperative healing and stabilize chronic inflammation as well.

 

Global Autologous Cell Therapy Market Analysis

Autologous cell therapies find their applications across several domains. It is associated with less adverse side effects that may persist due to foreign materials and incompatibility between host and outside cells. With the increasing emphasis on precision medicine, patients are showing their preference towards autologous cell therapies, which has led to significant market demand.

 

Then autologous cell therapy market value is used effectively in wound healing. Starting in the 1980s, bioengineered skin equivalents have been effective for wound healing outcomes. However, issues like scarring, skin contracture and poor epithelialization persisted in conventional methods. Hence, researchers have been working to develop an improved and efficient method to address the side effects. In July 2023, researchers reviewed the effectiveness of an autologous cell therapy called EB-101 to treat dystrophic epidermis bullosa (RDEB) in patients. It was revealed that 81%  of the wounds treated with EB-101 resulted in pain severity and healed effectively.

 

Around 3-5%  of the world’s population is affected by autoimmune diseases. Over the years, autologous cell therapies have been widely used in the treatment of autoimmune diseases. Currently, the treatment market is observing several technical innovations. In August 2023, Artiva Biotherapeutics announced that their new investigational drug got its FDA clearance to be used in the market. AlloNK® (also known as AB-101), comes in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients affected with active lupus nephritis (LN). Autologous CAR T-cell therapies are also used in treating selective blood cancer, predominantly B cell malignancies. Owing to its wide application, autologous cell therapy market demand is anticipated to increase in the forecast period.

 

Global Autologous Cell Therapy Market Segmentation

Market Breakup by Therapy

  • Autologous Stem Cell Therapy
  • Autologous Cellular Immunotherapies

 

Market Breakup by Source

  • Bone Marrow
  • Epidermis
  • Others

 

Market Breakup by Application

  • Oncology
  • Musculoskeletal Disorder
  • Blood Disorder
  • Autoimmune Disease
  • Others

 

Market Breakup by End User

  • Hospitals
  • Research Centres
  • Cancer Treatment Centres
  • Others

 

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Global Autologous Cell Therapy Market Overview

The global market for autologous cell therapy is constantly growing and witnessing significant attention as a potential treatment for many diseases. The active participation of various healthcare pioneers expediating research and development in the field. For instance, in June 2023, AstraZeneca announced an agreement with Quell Therapeutics to treat type 1 diabetes and inflammatory bowel disease with the help of developing autologous multi-modular Treg cell therapy.

 

The United States is expected to lead the market with latest investments in the infrastructure for better research and development. Bristol Myers Squibb got its FDA clearance to set up a commercial production for the company’s latest cell therapy manufacturing facility in Devens, Massachusetts. Therefore, United States will hold a huge portion of the autologous cell therapy market share in the forecast period. However, considering the technological and academic growth in the Asia Pacific, the region is anticipated to witness the fastest growth in upcoming years.

 

Global Autologous Cell Therapy Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Sanpower Group (Dendreon Pharmaceuticals LLC.)
  • Holostem Terapie Avanzate S.r.l.
  • Novartis AG
  • Tego Science
  • GC Biopharma (GC Cell)
  • Gilead Sciences
  • Johnson & Johnson (Janssen Biotech, Inc)
  • Bristol Myers Squibb
  • CORESTEM, Inc
  • Vericel Corporation
  • Opexa Therapeutics
  • Lineage Cell Therapeutics, Inc.
  • Pharmicell Co., Inc.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Therapy
  • Source
  • Application
  • End User
  • Region
Breakup by Therapy
  • Autologous Stem Cell Therapy 
  • Autologous Cellular Immunotherapies
Breakup by Source
  • Bone Marrow 
  • Epidermis 
  • Others
Breakup by Application
  • Oncology
  • Musculoskeletal Disorder 
  • Blood Disorder 
  • Autoimmune Disease 
  • Others
Breakup by End User
  • Hospitals 
  • Research Centers 
  • Cancer Treatment Centres
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Sanpower Group (Dendreon Pharmaceuticals LLC.)
  • Holostem Terapie Avanzate S.r.l.
  • Novartis AG
  • Tego Science
  • GC Biopharma (GC Cell)
  • Gilead Sciences
  • Johnson & Johnson (Janssen Biotech, Inc)
  • Bristol Myers Squibb
  • CORESTEM, Inc 
  • Vericel Corporation
  • Opexa Therapeutics
  • Lineage Cell Therapeutics, Inc.
  • Pharmicell Co., Inc.

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Autologous Cell Therapy Market Overview 

    3.1    Global Autologous Cell Therapy Market Historical Value (2017-2023) 
    3.2    Global Autologous Cell Therapy Market Forecast Value (2024-2032)
4    Global Autologous Cell Therapy Market Landscape
    4.1    Global Autologous Cell Therapy Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Autologous Cell Therapy Product Landscape
        4.2.1    Analysis by Therapy
        4.2.2    Analysis by Source
        4.2.3    Analysis by Application
5    Global Autologous Cell Therapy Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Autologous Cell Therapy Market Segmentation 
    6.1    Global Autologous Cell Therapy Market by Therapy
        6.1.1    Market Overview 
        6.1.2    Autologous Stem Cell Therapy 
        6.1.3    Autologous Cellular Immunotherapies
    6.2    Global Autologous Cell Therapy Market by Source
        6.2.1    Market Overview
        6.2.2    Bone Marrow 
        6.2.3    Epidermis 
        6.2.4    Others
    6.3    Global Autologous Cell Therapy Market by Application
        6.3.1    Market Overview
        6.3.2    Oncology
        6.3.3    Musculoskeletal Disorder 
        6.3.4    Blood Disorder 
        6.3.5    Autoimmune Disease 
        6.3.6    Others
    6.4    Global Autologous Cell Therapy Market by End User
        6.4.1    Market Overview
        6.4.2    Hospitals 
        6.4.3    Research Centers 
        6.4.4    Cancer Treatment Centres
        6.4.5    Others
    6.5    Global Autologous Cell Therapy Market by Region
        6.5.1    Market Overview
        6.5.2    North America 
        6.5.3    Europe
        6.5.4    Asia Pacific
        6.5.5    Latin America
        6.5.6    Middle East and Africa
7    North America Autologous Cell Therapy Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Autologous Cell Therapy Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Autologous Cell Therapy Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Autologous Cell Therapy Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Autologous Cell Therapy Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by Year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14     Clinical Trials Analysis
    14.1    Analysis by Trial Registration Year
    14.2    Analysis by Trial Status
    14.3    Analysis by Trial Phase
    14.4    Analysis by Therapeutic Area
    14.5    Analysis by Geography
15    Funding & Investment Analysis
    15.1    Analysis by Funding Instances
    15.2    Analysis by Type of Funding
    15.3    Analysis by Funding Amount
    15.4    Analysis by Leading Players
    15.5    Analysis by Leading Investors
    15.6    Analysis by Geography
16    Partnership and Collaborations Analysis
    16.1    Analysis by Partnership Instances
    16.2    Analysis by Type of Partnership
    16.3    Analysis by Leading Players
    16.4    Analysis by Geography
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Supplier Landscape
    18.1    Sanpower Group (Dendreon Pharmaceuticals LLC.)
        18.1.1    Financial Analysis
        18.1.2    Product Portfolio
        18.1.3    Demographic Reach and Achievements
        18.1.4    Mergers and Acquisitions
        18.1.5    Certifications
    18.2    Holostem Terapie Avanzate S.r.l.
        18.2.1    Financial Analysis
        18.2.2    Product Portfolio
        18.2.3    Demographic Reach and Achievements
        18.2.4    Mergers and Acquisitions
        18.2.5    Certifications
    18.3    Novartis AG
        18.3.1    Financial Analysis
        18.3.2    Product Portfolio
        18.3.3    Demographic Reach and Achievements
        18.3.4    Mergers and Acquisitions
        18.3.5    Certifications
    18.4    Tego Science
        18.4.1    Financial Analysis
        18.4.2    Financial Portfolio
        18.4.3    Demographic Reach and Achievements
        18.4.4    Mergers and Acquisitions
        18.4.5    Certifications
    18.5    GC Biopharma (GC Cell)
        18.5.1    Financial Analysis
        18.5.2    Product Portfolio
        18.5.3    Demographic Reach and Achievements
        18.5.4    Mergers and Acquisitions
        18.5.5    Certifications
    18.6    Gilead Sciences
        18.6.1    Financial Analysis
        18.6.2    Product Portfolio
        18.6.3    Demographic Reach and Achievements
        18.6.4    Mergers and Acquisitions
        18.6.5    Certifications
    18.7    Johnson & Johnson (Janssen Biotech, Inc)
        18.7.1    Financial Analysis
        18.7.2    Product Portfolio
        18.7.3    Demographic Reach and Achievements
        18.7.4    Mergers and Acquisitions
        18.7.5    Certifications
    18.8    Bristol Myers Squibb
        18.8.1    Financial Analysis
        18.8.2    Product Portfolio
        18.8.3    Demographic Reach and Achievements
        18.8.4    Mergers and Acquisitions
        18.8.5    Certifications
    18.9    CORESTEM, Inc 
        18.9.1    Financial Analysis
        18.9.2    Product Portfolio
        18.9.3    Demographic Reach and Achievements
        18.9.4    Mergers and Acquisitions
        18.9.5    Certifications
    18.10    Vericel Corporation
        18.10.1    Financial Analysis
        18.10.2    Product Portfolio
        18.10.3    Demographic Reach and Achievements
        18.10.4    Mergers and Acquisitions
        18.10.5    Certifications
    18.11    Opexa Therapeutics
        18.11.1    Financial Analysis
        18.11.2    Product Portfolio
        18.11.3    Demographic Reach and Achievements
        18.11.4    Mergers and Acquisitions
        18.11.5    Certifications
    18.12    Lineage Cell Therapeutics, Inc.
        18.12.1    Financial Analysis
        18.12.2    Product Portfolio
        18.12.3    Demographic Reach and Achievements
        18.12.4    Mergers and Acquisitions
        18.12.5    Certifications
    18.13    Pharmicell Co., Inc.
        18.13.1    Financial Analysis
        18.13.2    Product Portfolio
        18.13.3    Demographic Reach and Achievements
        18.13.4    Mergers and Acquisitions
        18.13.5    Certifications
19    Global Autologous Cell Therapy Market - Distribution Model (Additional Insight)
    19.1    Overview 
    19.2    Potential Distributors 
    19.3    Key Parameters for Distribution Partner Assessment 
20    Key Opinion Leaders (KOL) Insights (Additional Insight)
21    Company Competitiveness Analysis (Additional Insight)

    21.1    Very Small Companies
    21.2    Small Companies
    21.3    Mid-Sized Companies
    21.4    Large Companies
    21.5    Very Large Companies
22    Payment Methods (Additional Insight)
    22.1    Government Funded
    22.2    Private Insurance
    22.3    Out-of-Pocket
 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 7.8 billion in 2023, driven by the focus on treating chronic diseases with the help of precision medicine.

The market is anticipated to grow at a CAGR of 19.4% during the forecast period of 2024-2032, likely to reach a market value of USD 38.4 billion by 2032.

Autologous cell therapies are used in offering treatment for several domains including oncology, dermatology, and autoimmune diseases. Owing to its efficacy and lesser risk of dangerous side effects, the market demand has grown.

Global healthcare industry leaders are working on expanding their research and development in the field. For instance, AstraZeneca is aiming to develop autologous multi-modular Treg cell therapies to treat type 1 diabetes and inflammatory bowel diseases with the help of developing.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.

Common application areas include oncology, musculoskeletal disorder, blood disorder, autoimmune disease, and others.

Autologous stem cell therapy and autologous cellular immunotherapies are two therapies.

Sources include bone marrow and epidermis, among others.

Major end users include hospitals, clinics, research centres, and cancer treatment centres, among others.

Key players involved in the market are Sanpower Group (Dendreon Pharmaceuticals LLC.), Holostem Terapie Avanzate S.r.l., Novartis AG, Tego Science, GC Biopharma (GC Cell), Gilead Sciences, Johnson & Johnson (Janssen Biotech, Inc), CORESTEM, Inc., Vericel Corporation, Opexa Therapeutics, Lineage Cell Therapeutics, Inc., Pharmicell Co., Inc., and Bristol Myers Squibb.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER